Zoryl M 3mg/500mg Tablet PR

This dual mechanism addresses both insulin secretion and insulin resistance, making Zoryl M effective in patients inadequately controlled by diet and exercise alone. The prolonged-release formulation ensures sustained plasma drug levels, promoting better compliance and minimizing gastrointestinal side effects commonly associated with metformin. Zoryl M is typically prescribed as part of a comprehensive diabetes management plan, including diet modification and physical activity.

Caution is advised in patients with renal impairment, hepatic dysfunction, or conditions predisposing to hypoxia, as metformin carries a risk of lactic acidosis. Regular monitoring of blood glucose, renal function, and potential adverse effects is recommended during therapy. Zoryl M should not be used in type 1 diabetes or diabetic ketoacidosis. Dose adjustments may be necessary based on therapeutic response and tolerability.